TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE

通过PathogenDx的解决方案（DetectX-Rv），在接下来的四个月里，我们将为全国提供25倍的测试能力，而不会增加实验室房地产占地面积，不会增加无休止的立即贬值的测试系统，保持所需的准确测试水平，并且解决方案可以灵活地满足市场对不同尺寸SBS板的需求。 我们的建议是在相同的实际测试基质上将测试容量提高两倍~在不到4个月的时间内将相同的SBS板从12孔阵列玻片优化为96个威尔斯孔，最终优化为384孔格式。 实施这一策略将每月提供415万次测试，每次测试的成本节省55%和70%。相比之下，使用qRT-PCR技术部署相同的容量，RaDx的CapEx成本将是RaDx的五倍，每个测试成本将是RaDx的三倍。

With PathogenDx's solution (DetectX-Rv), over the next four months, we will deliver a 25 fold increase in test capacity for the nation without increasing  lab-real-estate footprint, without adding endless lines of testing systems that depreciate instantly, upholding the level of accurate testing needed, and a solution that can ‘flex’ to the demands of the market with the different sized SBS plates.  What we propose is quadrupling test capacity twice on the same actual test substrate ~ optimizing the same SBS plate from 12 well array slides to 96 wells ultimately to a 384 well format in less than 4 months.   Exercising this strategy will deliver 4.15M tests per month, and result in cost savings of 55% and 70% per test. As a comparison, to deploy the same capacity using qRT-PCR technology, it will cost RaDx five times as much in CapEx and three times more per test cost.